5 newsletters, ranked by editorial quality and how recently they published. Looking for something more specific? Search instead.
Long-form essays examining the scientific claims and limits of biological research, especially organoids in drug discovery, disease modeling, and Alzheimer's research. Readers get critical, detailed analysis of where lab models succeed, fail, and get overhyped, plus updates from the author's work on AI and health.
A personal-essay-driven newsletter on data, companies and ideas at the frontier of biology, covering topics like AI in drug discovery, the economics of pharma R&D and founder stories. Readers get long-form analysis of the biotech landscape, investments and historical context of life sciences.
Peter Diamandis-style essays on exponential technology, covering AI's effect on biotech, business moats, and education reform, often promoting his investments and Abundance360 community. Readers get big-picture futurist commentary with investment and entrepreneurial angles.
Companion podcast episode notes from Harvard professor David Sinclair and co-host Matthew LaPlante covering longevity science, including biological age testing, brain aging, and cosmetic aging. Each issue lists episode summaries, timestamps and links to the studies discussed.
Wezempic is a health newsletter focused on GLP-1 weight-loss medications such as Ozempic, Wegovy and Mounjaro, covering their long-term use, the science behind them and related biotech news. Its excerpts are generic, promotional and largely rewritten news, so readers get an overview of the topic rather than original expert analysis.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
